James Investment Research Inc. Sells 10,049 Shares of Danaher Corporation (NYSE:DHR)

James Investment Research Inc. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 60.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,695 shares of the conglomerate's stock after selling 10,049 shares during the period. James Investment Research Inc.'s holdings in Danaher were worth $1,372,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Welch & Forbes LLC lifted its holdings in shares of Danaher by 0.8% during the first quarter. Welch & Forbes LLC now owns 690,602 shares of the conglomerate's stock valued at $141,573,000 after purchasing an additional 5,749 shares during the last quarter. Cable Hill Partners LLC raised its holdings in Danaher by 77.3% in the 1st quarter. Cable Hill Partners LLC now owns 1,732 shares of the conglomerate's stock worth $345,000 after acquiring an additional 755 shares during the last quarter. Cullen Frost Bankers Inc. raised its holdings in Danaher by 1.7% in the 1st quarter. Cullen Frost Bankers Inc. now owns 134,220 shares of the conglomerate's stock worth $27,515,000 after acquiring an additional 2,266 shares during the last quarter. Bryn Mawr Capital Management LLC raised its holdings in Danaher by 2.2% in the 1st quarter. Bryn Mawr Capital Management LLC now owns 74,956 shares of the conglomerate's stock worth $15,366,000 after acquiring an additional 1,642 shares during the last quarter. Finally, Bridgewater Advisors Inc. purchased a new position in Danaher in the 1st quarter worth approximately $1,269,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR stock traded down $4.37 during mid-day trading on Friday, reaching $190.42. 1,479,416 shares of the company's stock traded hands, compared to its average volume of 3,513,918. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70. The firm has a 50 day moving average price of $196.12 and a two-hundred day moving average price of $205.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The firm has a market capitalization of $136.28 billion, a PE ratio of 36.96, a price-to-earnings-growth ratio of 2.71 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. On average, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher's dividend payout ratio is currently 24.85%.

Insider Buying and Selling at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. Argus decreased their price objective on shares of Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Royal Bank Of Canada restated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. The Goldman Sachs Group decreased their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Leerink Partners boosted their price objective on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Finally, Wolfe Research decreased their target price on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $248.48.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.